TITLE

Decreasing HIV Drug Resistance in the United Kingdom

PUB. DATE
September 2007
SOURCE
Clinical Infectious Diseases;9/1/2007, Vol. 45 Issue 5, pvi
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the study "A decreasing prevalence of antiretroviral drug resistance in the UK: evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom." In the study, the researchers conducted analysis of major resistance mutations to determine time-dependent changes in antiretroviral resistance. From the data gathered, the researchers found out a nationwide decrease in antiretroviral resistance. They stressed that such decrease may be the result of the availability of more effective therapy to HIV-positive persons.
ACCESSION #
26646513

 

Related Articles

  • Revertant multiresistant HIV in chronically infected drug naïve patients: when baseline resistance testing is not enough. Baraboutis, Ioannis G.; Papastamopoulos, Vassilios; Georgiou, Ourania; Skoutelis, Athanasios T. // International Journal of STD & AIDS;Oct2007, Vol. 18 Issue 10, p722 

    We present a patient with chronic HIV-1 infection and primary multi-drug resistance, the magnitude of which was underestimated by the baseline genotypic resistance testing (GRT) due to reversion of some of the mutations of the transmitted strain. This resulted in complete failure of his first...

  • Prevalence of Transmitted Drug Resistance and Impact of Transmitted Resistance on Treatment Success in the German HIV-1 Seroconverter Cohort. Bartmeyer, Barbara; Kuecherer, Claudia; Houareau, Claudia; Werning, Johanna; Keeren, Kathrin; Somogyi, Sybille; Kollan, Christian; Jessen, Heiko; Dupke, Stephan; Hamouda, Osamah // PLoS ONE;2010, Vol. 5 Issue 10, p1 

    Background: The aim of this study is to analyse the prevalence of transmitted drug resistance, TDR, and the impact of TDR on treatment success in the German HIV-1 Seroconverter Cohort. Methods: Genotypic resistance analysis was performed in treatment-naïve study patients whose sample was...

  • Long-term maraviroc use as salvage therapy in HIV-2 infection. Caixas, Umbelina; Ferreira, Joana; Marinho, Aline T.; Faustino, Inês; Grilo, Nádia M.; Lampreia, Fátima; Germano, Isabel; Monteiro, Emília C.; Pereira, Sofia A. // Journal of Antimicrobial Chemotherapy (JAC);Oct2012, Vol. 67 Issue 10, p2538 

    The article discusses the case of a patient diagnosed with human immunodeficiency virus (HIV)-2. Information on the patient's combined antiretroviral therapy (cART) is provided. Atazanavir/ritonavir served as substitutes to lopinavir/ritonavir due to the patient's intolerance and poor adherence...

  • Raltegravir: The First HIV Type 1 Integrase Inhibitor. Hicks, Charles; Gulick, Roy M. // Clinical Infectious Diseases;4/1/2009, Vol. 48 Issue 7, p931 

    Raltegravir is the first approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor; it targets the strand transfer step of HIV-1 integration. Clinical trials have demonstrated that raltegravir-containing regimens have potent antiretroviral activity and are well tolerated in...

  • Rate of Viral Evolution and Risk of Losing Future Drug Options in Heavily Pretreated, HIV-Infected Patients Who Continue to Receive a Stable, Partially Suppressive Treatment Regimen. Hatano, Hiroyu; Hunt, Peter; Weidler, Jodi; Coakley, Eoin; Hoh, Rebecca; Liegler, Teri; Martin, Jeffrey N.; Deeks, Steven G. // Clinical Infectious Diseases;11/15/2006, Vol. 43 Issue 10, p1329 

    Background. Many treatment-experienced, HIV-infected patients who have limited therapeutic options for complete viral suppression continue to receive a partially suppressive treatment regimen pending the availability of at least 2 new antiretroviral drugs. The major risk of this approach is...

  • HIV Drug Resistance Early Warning Indicators in Namibia with Updated World Health Organization Guidance. Jonas, Anna; Sumbi, Victor; Mwinga, Samson; DeKlerk, Michael; Tjituka, Francina; Penney, Scott; Jordan, Michael R.; Desta, Tiruneh; Tang, Alice M.; Hong, Steven Y. // PLoS ONE;Jul2014, Vol. 9 Issue 7, p1 

    Background: In response to concerns about the emergence of HIV drug resistance (HIVDR), the World Health Organization (WHO) has developed a comprehensive set of early warning indicators (EWIs) to monitor HIV drug resistance and good programme practice at antiretroviral therapy (ART) sites....

  • Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race-ethnicity determine the degree of regimen complexity. Tashima, Karen T.; Mollan, Katie R.; Na, Lumine; Gandhi, Rajesh T.; Klingman, Karin L.; Fichtenbaum, Carl J.; Andrade, Adriana; Johnson, Victoria A.; Eron, Joseph J.; Smeaton, Laura; Haubrich, Richard H. // HIV Clinical Trials;Aug2015, Vol. 16 Issue 4, p147 

    Background: Regimen selection for highly treatment-experienced patients is complicated. Methods: Using a web-based utility, study team members reviewed antiretroviral (ARV) history and resistance data and recommended individual ARV regimens and nucleoside reverse transcriptase inhibitor (NRTI)...

  • Evolution and viral characteristics of a long-term circulating resistant HIV-1 strain in a cluster of treatment-naive patients. Hofstra, L. Marije; Nijhuis, Monique; Pingen, Marieke; Mudrikova, Tania; Riezebos-Brilman, Annelies; Simoons-Smit, Alberdina M.; Van Ham, Petra M.; Bierman, Wouter F. W.; Wensing, Annemarie M. J. // Journal of Antimicrobial Chemotherapy (JAC);Jun2013, Vol. 68 Issue 6, p1246 

    Background Transmitted resistant HIV may revert to wild-type in the absence of drug pressure due to reduced replication capacity (RC). We observed eight therapy-naive patients infected with HIV harbouring four mutations at nucleoside reverse transcriptase inhibitor (NRTI) resistance-related...

  • HIV Resistance Testing. Deresinski, Stan // Clinical Infectious Diseases;3/15/2005, Vol. 40 Issue 6, preceding p1 

    The article presents information on HIV resistance testing. The most recent guidelines for antiretroviral therapy for HIV- 1-infected adults and adolescents, published on October 29, 2004, recommend the use of HIV drug resistance testing in 3 circumstances: virologic failure during combination...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics